Toggle navigation
Home
Search
Services
Blog
Contact
About
No. 73 a Phase Iia Cancer Prevention Trial of the Ppar/ Agonist Piogli-261015000
University of Minnesota Twin Cities, Minneapolis, MN, United States
Search grants from University of Minnesota Twin Cities
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Fred Hutchinson Cancer Research Center
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Single Channel Studies of the Fusion Pore
Medical Scientist Training Program
Training Program in Academic Gastroenterology
Falls and Fractures Among Elderly Japanese-Americans
Role of Fiber in Prevention of Colon Cancer
Recently added grants:
Optimizing Bilateral and Single-Sided Deafness Cochlear Implants for Functioning in Complex Auditory Environments
Restoration of spectral resolution with hearing-aid amplification
Influence of diet on the development of homeostatic neurocircuits
Optically Induced Anisometropia
Phosphorylation and ubiquitination of immune sensory complexes in innate immune signaling
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
Division of Cancer Prevention And Control (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CN015000-001
Application #
6994812
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2004
Total Cost
Indirect Cost
Institution
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Related projects
NIH 2006
N01 CN
No. 73 a Phase Iia Cancer Prevention Trial of the Ppar/ Agonist Piogli-261015000
/ University of Minnesota Twin Cities
NIH 2004
N01 CN
No. 73 a Phase Iia Cancer Prevention Trial of the Ppar/ Agonist Piogli-261015000
/ University of Minnesota Twin Cities
Publications
Rosas, R R; Cole, K A; Darrah, L et al.
(2012)
A comparison of screening methods in two early phase oral leukoplakia clinical trials.
Oral Dis 18:720-3
Comments
Be the first to comment on this grant